Dave Neustaedter

Dave Neustaedter has nearly 20 years of experience contributing to innovation in the life sciences industry as a venture capital and business development professional, a commercial strategist, and a scientific researcher. Prior to joining Covidien Ventures, Dave was Director of Commercial Strategy & Advanced Technologies at Stryker Development, LLC, where he was responsible for licensing, acquisition and venture investing in early stage medical technologies. He also led the division’s commercial strategy and financial reporting functions. Earlier in his career, as a strategy consultant at Leerink Swann and Fletcher Spaght, he helped operating companies and venture investors with numerous key decisions on internal investments and acquisition opportunities across the medical device, diagnostic and biopharmaceutical industries. Dave has an MBA from Yale and a PhD in molecular biology from the University of British Columbia. He completed post-doctoral work in bone development and neurodegenerative disease at the Mount Sinai School of Medicine and is a co-inventor on two medical device patent applications.